Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

GM-CSF inhibitor

DRUG CLASS:

GM-CSF inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

NRAS mutation	Chronic Myelomonocytic Leukemia	NRAS mutation	Chronic Myelomonocytic Leukemia	lenzilumab Sensitive: C2 – Inclusion Criteria lenzilumab Sensitive : C2	lenzilumab Sensitive: C2 – Inclusion Criteria lenzilumab Sensitive : C2
CBL mutation	Chronic Myelomonocytic Leukemia	CBL mutation	Chronic Myelomonocytic Leukemia	lenzilumab Sensitive: C2 – Inclusion Criteria lenzilumab Sensitive : C2	lenzilumab Sensitive: C2 – Inclusion Criteria lenzilumab Sensitive : C2
KRAS mutation	Chronic Myelomonocytic Leukemia	KRAS mutation	Chronic Myelomonocytic Leukemia	lenzilumab Sensitive: C2 – Inclusion Criteria lenzilumab Sensitive : C2	lenzilumab Sensitive: C2 – Inclusion Criteria lenzilumab Sensitive : C2